Perceptive Advisors LLC Revolution Medicines, Inc. Transaction History

Perceptive Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$26.56 - $33.55 $5.31 Million - $6.71 Million	-199,997 Reduced 24.42%	618,885 $19.9 Million
Q4 2023 Feb 14, 2024	SELL	$18.35 - $34.12 $9.23 Million - $17.2 Million	-502,913 Reduced 38.05%	818,882 $23.5 Million
Q3 2023 Nov 14, 2023	BUY	$25.17 - $35.05 $33.3 Million - $46.3 Million	1,321,795 New	1,321,795 $36.6 Million
Q3 2022 Nov 14, 2022	BUY	$17.46 - $26.0 $5.42 Million - $8.07 Million	310,500 New	310,500 $6.12 Million
Q1 2021 May 17, 2021	SELL	$37.21 - $54.43 $8.34 Million - $12.2 Million	-224,224 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$22.61 - $34.8 $2.84 Million - $4.38 Million	-125,776 Reduced 35.94%	224,224 $7.8 Million
Q1 2020 May 15, 2020	BUY	$20.0 - $34.08 $7 Million - $11.9 Million	350,000 New	350,000 $7.82 Million

299

179M

920K

1.06M

Ticker RVMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,697,600
Market Cap $3.63B
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.